KB-1223

Sacituzumab

52676

Background of Sacituzumab

Trop2 is a type I cell surface glycoprotein, which is limited in normal tissues but highly expressed in human tumor tissues. Overexpression of TROP2 can promote the growth, proliferation and metastasis of tumor cells. This differentiated expression of TROP2 protein makes it a new target for researchers to develop antibody-coupled drugs. Sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy™) is a Trop-2-directed antibody conjugated to a topoisomerase I inhibitor (SN-38) that is being developed by Immunomedics for the treatment of solid tumours, including breast cancer.

Specifications

Catalog Number	KB-1223
Antibody Name	Sacituzumab
Isotype	Human IgG1,kappa
FC Muations	Wild Type
Target	TROP2
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	FACS
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Hope S Rugo , Aditya Bardia , Sara M Tolaney , Carlos Arteaga , Javier Cortes , Joohyuk Sohn , Frederik Marmé , Quan Hong , Rosemary J Delaney , Amir Hafeez , Fabrice André , Peter Schmid . TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer.Future Oncol. 2020 Apr;16(12):705-715.
Aditya Bardia , Sara A Hurvitz , Sara M Tolaney , Delphine Loirat , Kevin Punie , Mafalda Oliveira , Adam Brufsky , Sagar D Sardesai , Kevin Kalinsky , Amelia B Zelnak , Robert Weaver , Tiffany Traina , Florence Dalenc , Philippe Aftimos , Filipa Lynce , Sami Diab , Javier Cortés , Joyce O'Shaughnessy , Véronique Diéras , Cristiano Ferrario , Peter Schmid , Lisa A Carey , Luca Gianni , Martine J Piccart , Sibylle Loibl , David M Goldenberg , Quan Hong , Martin S Olivo , Loretta M Itri , Hope S Rugo ; ASCENT Clinical Trial Investigators. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.N Engl J Med. 2021 Apr 22;384(16):1529-1541.